Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

Valneva SE (NASDAQ:VALN) saw a significant decline in short interest in January. As of January 15th, there was short interest totalling 15,900 shares, a decline of 34.6% from the December 31st total of 24,300 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 38,300 shares, the days-to-cover ratio is currently 0.4 days.

Valneva Stock Performance

Valneva stock opened at $5.69 on Friday. The company’s 50-day moving average is $4.32 and its two-hundred day moving average is $5.72. The company has a market cap of $461.96 million, a PE ratio of -43.73 and a beta of 1.93. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its holdings in Valneva SE (NASDAQ:VALN) by 33.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Valneva in a research report on Friday.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.